Abnormal signaling of the protein kinase Akt has been shown to contribute to human diseases such as diabetes and cancer, but Akt has proven to be a challenging target for drugging. Using iterative in situ click chemistry we recently developed multiple protein catalyzed capture (PCC) agents that allosterically modulate Akt enzymatic activity in a protein based assay. Here we utilize similar PCCs to exploit endogenous protein degradation pathways. We use the modularity of the anti-Akt PCCs to prepare Proteolysis Targeting Chimeric molecules (PROTACs) that are shown to promote the rapid degradation of Akt in live cancer cells. These novel PROTACs demonstrate that the epitope targeting selectivity of PCCs can be coupled with non-traditional drugging moieties to inhibit challenging targets.
INTRODUCTION
Protein-catalyzed capture agents (PCCs) are a class of ligands that are built using in situ click chemistry (Lewis et al., 2002) to allow a protein of interest to select its own highaffinity binders (Agnew et al., 2009 ). These synthetic peptides have some similarities to monoclonal antibodies, but are a fraction of the size and can exhibit a high level of stability Pfeilsticker et al., 2013) . A recent advance of this technology permits the targeted development of a PCC against a specific epitope of a given protein Farrow et al., 2015; Nag et al., 2013) . Unlike the case for small molecule ligands, the generalized PCC epitope targeting strategy does not rely on the presence of a hydrophobic binding pocket. This opens up several non-traditional approaches towards altering enzymatic activity, including the targeting of sites that can allosterically influence that activity (Millward et al., 2011) or by disrupting protein-activator associations . A second possibility is simply to use the synthetic flexibility of the PCC as a selective targeting moiety for labeling the target with a molecular signal, such as a degradation signal, as is used for the case of Proteolysis Targeting Chimeric molecules (PROTACs). Here we explore the use of an epitope targeted PCC developed against an allosteric site of Akt2 as an in-cell allosteric activator and PROTAC.
Akt is a serine/threonine protein kinase with three closely related isoforms (Akt1-3) and is involved in cellular processes such as glucose metabolism, apoptosis, and cell proliferation (Engelman, 2009; Manning and Cantley, 2007) . Aberrant Akt signaling is implicated in diabetes and in many cancers, making it an attractive drug and diagnostic target (Lawlor and Alessi, 2001) . We previously reported the development of a PCC targeting the C-terminal hydrophobic motif (HM) of Akt2 that includes the Ser474 residue (Nag et al., 2013) . Phosphorylation of Akt at Ser474 leads to allosteric activation of Akt and increases the kinase activity 10 fold (Yang et al., 2002) . We thus hypothesized that targeting the Ser474 site could lead to compounds that influence Akt kinase activity. We increased the interaction footprint of the PCC with Akt2 by expanding it into two distinct triligands through in situ click chemistry screens. One of the triligands, tri_a, was shown to allosterically activate Akt enzymatic activity in in vitro kinase assays (Nag et al., 2013) .
Although specific peptides (typically macrocycles) have been designed for cell entry (Chu et al., 2015) , the tri_a PCC is a branched structure consisting of linear branches, and so does not naturally enter into live cells. We recently reported on a strategy for the delivery of PCCs into cells. The target of the PCC was a cell-penetrating enzyme (Botulinum Neurotoxin Serotype A), and so the PCC was carried into cells as a type of Trojan horse cargo . A second more common approach (Hassane et al., 2009 ) is to append a cell penetrating peptide (CPP) to the PCC, and that is the route we choose here. CPP-labeled tri_a was found to penetrate into live cells. The influence of that compound on in-cell kinase activity and on cellular proliferation was then explored in two cancer cell lines. We next modified the tri_a to present a HIF-1α degradation signal, and explored the capacity of this compound to promote in-cell Akt degradation.
RESULTS AND DISCUSSION
We conjugated the PCC agent to the HIV TAT peptide, which is a CPP that efficiently penetrates cell membranes via endocytosis, and allows CPP-bound molecules to enter cells (Heitz et al., 2009) . Figure 1A shows the structure of TAT-conjugated tri_a, where the TAT sequence is separated from the capture agent by two PEG spacers placed on either side of a protected-lysine residue. This permits further functionalization as desired during the solid phase peptide synthesis via the ε-amino group (adding a dye, signaling peptide, etc.). To validate cellular uptake, we treated U87 cells with fluorescein-labeled tri_a (CPP-tri_a-FL, Figure 1B ) and acquired simultaneous fluorescence and transmission images. U87 cells are particularly useful for imaging since they grow in a uniform monolayer (Camphausen et al., 2005) . We found that the CPP-tri_a-FL is able to efficiently penetrate the cell membrane and enter the cells. No fluorescence signals were detected outside the cells, and the uniform distribution of the fluorescence through the cell cytoplasm suggests that the PCCs were released into the cells (rather than completely trapped within endosomes).
We next performed functional assays to confirm that the in vitro effects translate into live cells. The enzymatic activity of Akt can be monitored by measuring the phosphorylated level of its direct substrate, glycogen synthase kinase 3 beta (GSK-3β) (Engelman, 2009 ). SKOV3 ovarian cancer cells were dosed with TAT-coupled tri_a (CPP-tri_a, Figure 1A , S1) for various times. Following cell lysis, the relative levels of various proteins were measured via western blotting ( Figure 2A ). Both untreated cells and EGF-stimulated cells were used as controls. The level of phospho(p)-GSK-3β was seen to increase after 1 hour of treatment, decrease over the next few hours, and finally increase once more -perhaps alluding to a feedback mechanism in the cell. The initial increase in the p-GSK-3β level indicates that the capture agent is binding Akt and stimulating its enzymatic activity in cells. The p-Akt level initially increases and then steadily decreases over time. Notably, EGF-stimulated cells display a large increase in p-Akt, but the corresponding level of p-GSK-3β in EGFstimulated cells is still lower than the initial levels in cells treated with CPP-tri_a.
We next performed an XTT cell proliferation assay to determine if Akt activation by CPPtri_a stimulates cell proliferation (Xu et al., 2012) . Dehydrogenase enzymes in live cells reduce XTT tetrazolium salt to a vividly colored formazan dye that can be used to quantify the number of viable cells (Berridge et al., 2005; Scudiero et al., 1988) . We found that CPPtri_a affected both OVCAR3 and SKOV3 cell lines ( Figure 2B ). Interestingly, for both cell lines, a sharp increase in proliferation after 24 hours is followed by a steady decrease over a few days -once more suggesting a possible feedback mechanism. Eventually, after several days of treatment, cellular proliferation falls back to baseline levels for SKVO3 cells while OVCAR3 cells are inhibited relative to the untreated control. An initial increase in cell number after treatment with CPP-tri_a is consistent with previous studies showing that Akt activation promotes cell cycle progression during the G1 and G2 phases of the cell cycle (Kandel et al., 2002; Ramaswamy et al., 1999) . Additionally, activated Akt is known to inhibit the pro-apoptotic Bad protein (Datta et al., 1997; Peso et al., 1997) , as well as the FoxO and Myc family of proteins (Arden, 2004; Zhu et al., 2008) . Such enhanced cell proliferation can be used in beneficial ways. Many pathological disorders are associated with aberrant cell death signaling, including various neurodegenerative diseases (Mattson and Sherman, 2003) . Akt activation was recently shown to prevent neuronal cell death (Jo et al., 2012) . Thus, an Akt activator might prove useful as a tool to probe the Akt signaling pathway and to help develop potential therapeutics for disease-associated apoptosis abnormalities. In any case, these results further corroborate the in vitro data that tri_a directly activates Akt.
PROTACs represent an example of using cellular signals to control levels of specific proteins (Buckley and Crews, 2014; Sakamoto et al., 2001 ). In particular, PROTACs utilize the quality-control machinery of the cell by artificially labeling proteins for proteasomal degradation. We sought to turn CPP-tri_a into a PROTAC (CPP-tri_a-PR, Figure 3 , S1) by encoding a peptide ligand for the E3 ubiquitin ligase von Hippel Lindau protein (VHL) directly into the CPP-labeled PCC agents (Hines et al., 2013) . The peptide represents the VHL binding site from hypoxia-inducible factor (HIF-1α) protein.
When OVCAR3 cells were treated with CPP-tri_a-PR over a variable time period up to 24 hours Akt levels diminished. After 30 minutes of treatment, a relative decrease in Akt level was measurable, with a continuing decrease that reached a nadir after 4 hours ( Figure 3A) . Similarly, an inhibitory capture agent, CPP-tri_i (see Fig S2 for inhibition data) , was also modified into a PROTAC (CPP-tri_i-PR, Figure S3 ) and also effectively removed Akt from cells (supplemental information), with a slightly slower time constant. We also observed a dose-dependent decrease in Akt upon treatment with the CPP-tri_a-PR, and determined an EC 50 degradation constant of 128±19 μM ( Figure 3B ).
SIGNIFICANCE
Previous PROTACs have been developed by adding a degradation signal to a modified protein ligand (Rodriguez-Gonzalez et al., 2008) or previously discovered inhibitors (Gustafson et al., 2015; Long et al., 2012 ). Here we report that an epitope-targeted PCC can be modified into a PROTAC to direct synthetic degradation to specific proteins in cells. We also show an Akt activator and inhibitor can both serve as PROTACs (Figure 3 and Supplement), indicating that ubiquitination and degradation of this protein can be induced regardless of the activation state of the protein. Targeting proteins for enzymatic destruction is an attractive alternative to developing traditional small molecule inhibitors, especially for proteins (such as Akt) that are difficult to inhibit with traditional methods (Neklesa and Crews, 2012) .
The principle concept reported here is the use of an epitope targeted PCC as simply a vehicle for directing PROTAC-initiated degradation to a specific target. A limitation of this approach, as reported, is that the PCCs are not intrinsically cell penetrant, and so were modified with a CPP for the in-cell assays. We have recently reported on epitope targeted macrocyclic PCCs , and such peptide architectures have been modified for both cell permeability (Chu et al., 2015; Hewitt et al., 2015; Walensky and Bird, 2014) and other desired pharmacokinetic properties (Bock et al., 2013) . Other promising proteolysis tags include members of the IMiD family, such as thalidomide, which is a drug with a rich history (Bartlett et al., 2004) . In 2010 it was discovered that thalidomide targets the E3 ubiquitin ligase member cereblon (Ito et al., 2010) . Related examples of cereblon-targeted degradation include the use of pomalidomide (Lu et al., 2015) and phthalimide (Winter et al., 2015) for PROTAC development.
EXPERIMENTAL PROCEDURES Peptide Synthesis
All peptides were synthesized via solid phase peptide synthesis as described previously (Nag et al., 2013) 
Cell culture
All cell lines were purchased from American Type Culture collection. U87 (ATCC number HTB14), OVCAR3 (ATCC number HTB161), SKOV3 (ATCC number HTB77) cells were cultured under conditions specified by the provider.
Fluorescence microscopy
Cells were seeded onto chambered coverglass slides (Sigma) and allowed to attach overnight. The following day, cells were serum starved and treated with fluorescent capture agent. Live cells were then imaged using a Zeiss LSM 5 Exciter microscope in the Caltech Biological Imaging Center.
Immunoblotting
Western blots were performed according to standard protocols. Briefly, cells were lysed with cell lysis buffer (Cell Signaling Technology) containing protease and phosphatase inhibitors (Cell Signaling Technology). Cell lysates were quantified with a Bradford protein assay (Thermo Scientific) and prepared for gel electrophoresis in Laemmli sample buffer and reducing agent. 20 μg of cell lysate were added to precast polyacrylamide gels (Bio-Rad) and proteins were separated by electrophoresis followed by transfer to PVDF membrane. Membranes were then blocked and probed with primary antibodies followed by horseradish peroxidase-conjugated secondary antibodies. The bands were visualized chemiluminescent substrate (Thermo Scientific). The following antibodies were used according to manufacturer protcol: p-GSK3β (Cell Signaling, 9323), GSK3 β (Cell Signaling, 12456), AKT (Cell Signaling, 4691), p-AKT (S473) (Cell Signaling, 4060), Actin (Cell Signaling, 8456), HRP-linked Anti-rabbit IgG (Cell Signaling, 7074).
Cell Proliferation Assay
XTT assay kit was purchased from Cell Signaling Technology (#9095) and used according to manufacturer protocol. Briefly, 1×10 4 cells/well were seeded in a 96-well plate. The following day, cells were serum starved and treated with PCC agent. Following treatment, XTT was added to the media and after 1 hour the absorbance at 450 nm was measured.
In-cell ELISA assay
In-cell ELISA kits were purchased from Thermo Scientific (#62215) and used according to manufacturer protocol. Briefly, 1×10 4 cells were seeded in 384-well plates and allowed to attach overnight. The following day, cells were serum starved and treated with capture agent. Following capture agent treatment, cells were fixed, permeablized, blocked, and then stained with primary and HRP-conjugated secondary antibody and developed with colorimetric peroxidase substrate. The absorbance was measured at 450 nm to quantify the protein. Cells were then incubated with Janus Green whole-cell stain and the absorbance was measured at 615 nm to quantify relative number of cells per well. The Akt signal was then normalized to the relative cell number for each well to determine the Akt/cell.
In Brief
A Protein Catalyzed Capture Agent (PCC) was developed against the C-terminal hydrophobic motif of Akt, a traditionally "undruggable" site, and shown to be an allosteric activator. Functionalization of the PCC with a degradation tag led to a new antiAkt PROTAC. 
